Stock comparison
Bio-Techne
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
TECH
Bio-Techne
Market cap
$7.55B
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
United Therapeutics UTHR
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | TECH | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 55C | 71B | UTHR |
| Benjamin Graham | 89A | 76B | TECH |
| Philip Fisher | 50C | 76B | UTHR |
| Peter Lynch | 24F | 62C | UTHR |
| Joel Greenblatt | 50D | 46D | TECH |
| Charlie Munger | 45D | 64C | UTHR |
| Terry Smith | 44D | 64C | UTHR |
Side-by-side metrics
| Metric | TECH | UTHR |
|---|---|---|
| Market cap | $7.55B | $24.13B |
| P/E (TTM) | 61.6x | 19.2x |
| EV/EBIT | 67.1x | 15.2x |
| ROIC (TTM) | 4.75% | 18.81% |
| Gross margin | 64.96% | 86.58% |
| Net margin | 9.05% | 40.61% |
| Revenue CAGR 5y | 6.98% | 17.22% |
| EPS CAGR 5y | -15.23% | 29.84% |
| Debt / Equity | 0.1x | - |
| Dividend yield | 0.74% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
TECH leads on
- Dividend yield0.74%vs 0.0%+100%
UTHR leads on
- EPS CAGR 5y29.84%vs -15.23%+151%
- Debt / Equity-vs 0.1x+100%
- Net margin40.61%vs 9.05%+78%
- EV/EBIT15.2xvs 67.1x+77%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.